ClinicalTrials.gg
RecruitingNCT05602246STARSUpdated Mar 19, 2026

Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS

An interventional study of Transobturator cystocele repair and Anterior colporrhaphy in Pelvic Organ Prolapse, Cystocele and Cystocele and Incomplete Uterovaginal Prolapse, sponsored by Charles University, Czech Republic. Recruiting at 8 sites in 2 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Primary conditionCystoceleRegistry: Pelvic Organ ProlapseReclassifiedWhy we changed it
Registry
Pelvic Organ Prolapse — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cystocele
Why
  1. The study's listed conditions name Cystocele, a narrower term within Pelvic Organ Prolapse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Charles University, Czech Republic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
592
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Study summary

Surgical correction of the prolapse in the anterior compartment remains one of the major challenges in urogynecology. Paravaginal defect in level II of vaginal fixation results in the majority of cystoceles. Clinically, these defects are often combined and/or may be bilateral. Hence, careful assessment and individualized planning of the surgical procedure is essential to optimize cystocele repair outcome. Several surgical techniques and approaches have been used for cystocele repair. After the ban on transvaginal meshes, the interest in native tissue repair has risen. Paravaginal defect repair is an effective surgery for paravaginal defect reconstruction. There is a current trend to utilize transvaginal surgery instead of more invasive transabdominal surgery. A novel method of transvaginal paravaginal defect repair - TOCR (transobturator cystocele repair) was suggested. The principle objective of the present trial is to compare its efficacy and safety to preexisting method of native tissue cystocele repair.

Read the detailed description

Pelvic organ prolapse (POP) has a negative impact on the quality of life of affected women and anterior compartment defects remain the most challenging to repair. It was reported that a women has almost a 1 in 5 risk of needing any kind of POP surgery in her lifetime, with anterior wall repair accounting for 40.6% of all of these. Depending on the structures affected, cystocele can be secondary to defects at: A) Level I vaginal support, provided by the uterosacral and cardinal ligaments or B) Level II vaginal support, mainly provided by the pubocervical fascia. Level II defects can be midline or lateral (paravaginal) depending on whether the fascia is weak at the midline or detached from its lateral attachment to the arcus tendineus fasciae pelvis (ATFP). Clinically, these defects are often combined and/or may be bilateral. Hence, careful assessment and individualized planning of the surgical procedure is essential to optimize cystocele repair outcome.

Several surgical techniques and approaches have been used for cystocele repair. These involve native tissue and the use of mesh implanted transvaginally and / or transabdominally.The mainstay for the vaginal repair of a level I defects is to anchor the uterine cervix or vaginal vault to the sacrospinous or the anterior longitudinal ligaments. However, proper restoration of a level II defect is more complex. Although, a classical anterior colporrhaphy might be suitable to correct an isolated midline weakness in the endopelvic fascia, it is suboptimal, on its own, for the repair an associated lateral defect, which is a common association. Indeed, De Lancey reported that paravaginal defects (PVDs) were diagnosed in 89% of women undergoing surgery for cystocele and stress urinary incontinence.

Although a variety of techniques for paravaginal defect repair (PVDR) have been suggested, several of these are now not feasible in many countries following the FDA's ban on transvaginal mesh manufacture, sale and distribution. Therefore, currently there are attempts to utilize minimally invasive approaches and modern devices in PVDR native tissue repair. Applying this principle, e.g. Capio Suture Capturing Device (Boston Scientific) has been proposed to re-attach the vagina to the ATFP using two to four non-absorbable sutures. However, based on anatomical observation, the ATFP is thin its superior part and thicker inferiorly. This is an issue that might affect the reliability of identifying and ensuring a secure anchorage to the ATFP when solely using a transvaginal route. Recently a novel. Technique of PVDR, called transobturator cystocele repair has been published. However, as the technique was described recently, no follow-up data have been reported to support its practice.

The aim of this randomized controlled trial (RCT) is to compare the novel TOCR and standard anterior colporrhaphy (AR) regarding their safety, efficacy and quality-of-life improvement in a one-year follow-up.

02

Conditions studied

  • Pelvic Organ Prolapse
  • Cystocele
  • Cystocele and Incomplete Uterovaginal Prolapse

Browse trials for

Keywords

  • Pelvic organ prolapse
  • Quality of life
  • TOCR
  • Anterior vaginal wall repair
  • Transobturator cystocele repair
03

In context

Cystocele Reclassified

71 studies on the registry are indexed under Cystocele; 5 are open to participants now.

This study's planned enrollment of 592 is above the median of 75 across 46 interventional studies indexed under Cystocele.

Browse Cystocele studies →

Lead sponsor

Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.

Compared within Cystocele, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pelvic Organ Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (at least) 2nd stage prolapse of the anterior compartment (Ba ≥ -1)
  • Age ≥ 50 years
  • Symptom bulge
  • Ability to speak Czech or English

Exclusion criteria

Exclusion Criteria:

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
592 participants (estimated)

Study arms

  • Experimental
    Transobturator cystocele repair (TOCR)

    The technique of TOCR was published previously including a video \[Kalis et al. Trans-obturator cystocele repair (TOCR) of level 2 paravaginal defect. Int Urogynecol J. 2020, 31(11):2435-38. doi:10.1007/s00192-020-04337-x\]. The anterior vaginal wall is incised in the midline and the pubocervical fascia is dissected to open the paravaginal space towards the ATFP and the fascia of the obturator internus muscle. 3-4 continuous non-locking stitches of non-absorbable suture 1-0 Ti-Cron™ braided polyester are taken into the pubocervical fascia and threaded using Shirodkar needles through skin incisions in genitofemoral sulci passing through the full thickness of the obturator membrane, obturator internus muscle. After closure of the vaginal skin incision, both ends of the Ti-Cron™ sutures are tied ensuring the obliteration of the paravaginal defect. Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management.

    Procedure: Transobturator cystocele repair

  • Active comparator
    standard anterior colporrhaphy (anterior repair - AR)

    The anterior vaginal wall is incised in the midline from the level of the bladder neck up to vaginal apex or anterior vaginal fornix. The bladder is sharply dissected from the vaginal wall with pubocervical fascia attached to the bladder wall. The fascia is approximated in the midline with several simple interrupted 0 polyglactin 910 sutures or equivalent. The surplus of distended vaginal epithelium is trimmed. The vaginal incision is closed using a continuous non-locking polyglactin 910 2-0 suture or equivalent. Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management.

    Procedure: Anterior colporrhaphy

Interventions

  • ProcedureTransobturator cystocele repair

    Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.

    Also known as: TOCR

  • ProcedureAnterior colporrhaphy

    The traditional transvaginal surgery for cystocele treatment used as a comparator in the study

    Also known as: Anterior repair

06

What researchers measure

Primary outcomes

  1. Anatomic failure

    Anterior compartment pelvic organ prolapse stage ≥ 2( i.e. pelvic organ prolpase quantification (POPQ) point Ba, or C of \> -1)

    Time frame: 1 year

Secondary outcomes

  1. Composite surgery failure

    Composite measure requiring at least one from the following: 1. anatomic failure (Pelvic Organ Prolapse Quantification point Ba, Bp, or C of \> 0), 2. subjective failure (presence of bothersome vaginal bulge symptoms), or 3. pessary or surgical retreatment for pelvic organ prolapse

    Time frame: 1 year

  2. 2-year composite surgery failure

    Composite measure requiring at least one from the following: 1. anatomic failure (Pelvic Organ Prolapse Quantification point Ba, Bp, or C of \> 0), 2. subjective failure (presence of bothersome vaginal bulge symptoms), or 3. pessary or surgical retreatment for pelvic organ prolapse

    Time frame: 2 years

  3. 2-year anatomic failure

    Anterior compartment pelvic organ prolapse stage ≥ 2( i.e. POPQ point Ba, or C of \> -1)

    Time frame: 2 years

  4. Complication rate

    Number of complications Dindo-Clavien Grade \> 2

    Time frame: 1 year

  5. Pain after the surgery

    visual analog scale (VAS) ≥ 3 (range 0-10, higher is worse)

    Time frame: Postoperative day 14

  6. Subjective perception of improvement

    Patient global impression of improvement (PGI-I) ≤ 2 (range 1-7, higher is worse)

    Time frame: 1 year

  7. 2-year subjective perception of improvement

    PGI-I ≤ 2 (range 1-7, higher is worse)

    Time frame: 2 years

  8. Patient satisfaction

    Subjectively assessed by the patient on a scale 0 - 100%. Satisfaction with the surgery ≥ 80 %.

    Time frame: 1 year

  9. De novo stress urinary incontinence (SUI)

    Any new stress leaks of urine reported by the patient ≥ once a week, or treatment

    Time frame: 1 year

  10. De novo overactive bladder (OAB)

    de novo OAB ≥ once a week, or treatment

    Time frame: 1 year

  11. Change in quality of life - urinary incontience

    assessed by Urinary Distress Inventory (UDI-6) score, range 0-100, higher is worse

    Time frame: 1 year

  12. Change in quality of life - prolapse bother

    assessed by Pelvic Organ Prolapse Distress Inventory (POPDI-6) score, range 0-100, higher is worse

    Time frame: 1 year

  13. Change in quality of life - anorectal problems

    assessed by Colorectal-Anal Distress Inventory (CRADI-8) score,range 0-100, higher is worse.

    Time frame: 1 year

  14. Change in quality of sexual life

    assessed by Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) single summary score in sexually active women (higher is better)

    Time frame: 1 year

  15. Change in severity of urinary incontinence

    assessed by International Consultation of Incontinence Questionnaire - Short Form (ICIQ-UI SF) score (0-21, higher is worse)

    Time frame: 1 year

07

Study locations

1 of 8 sites recruiting
  • Faculty of Medicine in Hradec Kralove, Charles University
    Hradec Králové, 500 05, Czechia
    Not yet recruiting
  • Medical Faculty, Ostrava University
    Ostrava-Poruba, 708 52, Czechia
    Not yet recruiting
  • Hospital Pardubice Region, Inc.
    Pardubice, 530 03, Czechia
    Not yet recruiting
  • Faculty of Medicine in Pilsen, Charles University
    Pilsen, 30000, Czechia
    Recruiting
  • Hospital na Bulovce, 1st Medical Faculty, Charles University
    Prague, 18000, Czechia
    Not yet recruiting
  • Tomas Bata Regional Hospital in Zlin
    Zlín, 762 75, Czechia
    Not yet recruiting
  • Košice Medical University
    Košice, 040 11, Slovakia
    Not yet recruiting
  • Trenčianska univerzita Alexandra Dubčeka
    Trenčín, 911 01, Slovakia
    Not yet recruiting
08

References and documents

Publications

  • Lowenstein E, Ottesen B, Gimbel H. Incidence and lifetime risk of pelvic organ prolapse surgery in Denmark from 1977 to 2009. Int Urogynecol J. 2015 Jan;26(1):49-55. doi: 10.1007/s00192-014-2413-y. Epub 2014 May 20. PubMed 24842118 ↗
  • Otcenasek M, Gauruder-Burmester A, Haak LA, Grill R, Popken G, Baca V. Paravaginal defect: A new classification of fascial and muscle tears in the paravaginal region. Clin Anat. 2016 May;29(4):524-9. doi: 10.1002/ca.22694. Epub 2016 Feb 14. PubMed 26800142 ↗
  • Arenholt LTS, Pedersen BG, Glavind K, Glavind-Kristensen M, DeLancey JOL. Paravaginal defect: anatomy, clinical findings, and imaging. Int Urogynecol J. 2017 May;28(5):661-673. doi: 10.1007/s00192-016-3096-3. Epub 2016 Sep 17. PubMed 27640064 ↗
  • Arenholt LTS, Pedersen BG, Glavind K, Greisen S, Bek KM, Glavind-Kristensen M. Prospective evaluation of paravaginal defect repair with and without apical suspension: a 6-month postoperative follow-up with MRI, clinical examination, and questionnaires. Int Urogynecol J. 2019 Oct;30(10):1725-1733. doi: 10.1007/s00192-018-3807-z. Epub 2018 Dec 1. PubMed 30506182 ↗
  • de Tayrac R, Boileau L, Fara JF, Monneins F, Raini C, Costa P. Bilateral anterior sacrospinous ligament suspension associated with a paravaginal repair with mesh: short-term clinical results of a pilot study. Int Urogynecol J. 2010 Mar;21(3):293-8. doi: 10.1007/s00192-009-1036-1. PubMed 19924370 ↗
  • Ward RM, Sung VW, Clemons JL, Myers DL. Vaginal paravaginal repair with an AlloDerm graft: Long-term outcomes. Am J Obstet Gynecol. 2007 Dec;197(6):670.e1-5. doi: 10.1016/j.ajog.2007.08.067. PubMed 18060976 ↗
  • Chinthakanan O, Miklos JR, Moore RD. Laparoscopic Paravaginal Defect Repair: Surgical Technique and a Literature Review. Surg Technol Int. 2015 Nov;27:173-83. PubMed 26680393 ↗
  • Delancey JO. Fascial and muscular abnormalities in women with urethral hypermobility and anterior vaginal wall prolapse. Am J Obstet Gynecol. 2002 Jul;187(1):93-8. doi: 10.1067/mob.2002.125733. PubMed 12114894 ↗
  • Holt E. US FDA rules manufacturers to stop selling mesh devices. Lancet. 2019 Apr 27;393(10182):1686. doi: 10.1016/S0140-6736(19)30938-9. No abstract available. PubMed 31034366 ↗
  • Leffler KS, Thompson JR, Cundiff GW, Buller JL, Burrows LJ, Schon Ybarra MA. Attachment of the rectovaginal septum to the pelvic sidewall. Am J Obstet Gynecol. 2001 Jul;185(1):41-3. doi: 10.1067/mob.2001.116366. PubMed 11483901 ↗
  • Kalis V, Kovarova V, Rusavy Z, Ismail KM. Trans-obturator cystocele repair of level 2 paravaginal defect. Int Urogynecol J. 2020 Nov;31(11):2435-2438. doi: 10.1007/s00192-020-04337-x. Epub 2020 Jun 3. PubMed 32494957 ↗
  • Jelovsek JE, Gantz MG, Lukacz E, Sridhar A, Zyczynski H, Harvie HS, Dunivan G, Schaffer J, Sung V, Varner RE, Mazloomdoost D, Barber MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Success and failure are dynamic, recurrent event states after surgical treatment for pelvic organ prolapse. Am J Obstet Gynecol. 2021 Apr;224(4):362.e1-362.e11. doi: 10.1016/j.ajog.2020.10.009. Epub 2020 Oct 8. PubMed 33039390 ↗
  • Delacroix C, Allegre L, Chatziioannidou K, Gerard A, Fatton B, de Tayrac R. Anterior bilateral sacrospinous ligament fixation with concomitant anterior native tissue repair: a pilot study. Int Urogynecol J. 2022 Dec;33(12):3519-3527. doi: 10.1007/s00192-022-05092-x. Epub 2022 Feb 28. PubMed 35226145 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2029, 83 months after the start.

Of 19 interventional studies with no phase under Cystocele, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2022
First posted
Nov 2, 2022
StartActual
Dec 1, 2022
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2034
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05602246
Responsible party
Zdenek Rusavy (assoc. prof. MD PhD, Charles University, Czech Republic) — Principal investigator
First posted
Nov 2, 2022
Start date
Dec 1, 2022
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2034 (estimated)
Last update
Mar 19, 2026

Study contacts

Vladimir Kalis, prof. MD PhD
Contact
kalisv@fnplzen.cz
+420377105228
Zdenek Rusavy, assoc. prof. MD PhD
Contact
rusavyz@fnplzen.cz
+420377105440
Vladimir Kalis, prof. MD PhD
study chair · Faculty of Medicine in Plzen, Charles University
Khaled MK Ismail, MBBCh, MSc, MD, PhD, FRCOG
study director · Faculty of Medicine in Plzen, Charles University
Zdenek Rusavy, assoc. prof. MD PhD
principal investigator · Faculty of Medicine in Plzen, Charles University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion